Track topics on Twitter Track topics that are important to you
Carfilzomib is an irreversible, epoxyketone proteasome inhibitor, whereas bortezomib is a reversible, boronic acid-based proteasome inhibitor. The randomised phase 3 ENDEAVOR study directly compared carfilzomib (56 mg/m2) plus dexamethasone with bortezomib (1·3 mg/m2) plus dexamethasone in patients with relapsed or refractory multiple myeloma who had received between one and three previous therapies. The first pre-specified interim analysis showed that patients in the carfilzomib group had higher rates of deeper responses, which translated into significantly longer progression-free survival than those who received bortezomib (median progression-free survival 18·7 months [95% CI 15·6–not estimable] vs 9·4 months [8·4–10·4], hazard ratio [HR] 0·53 [95% CI 0·44–0·65]; p<0·0001).
Original Article: [Comment] Carfilzomib versus bortezomib: no longer an ENDEAVORNEXT ARTICLE